“Pembrolizumab Plus Trastuzumab and Chemotherapy for HER2-Positive Gastric or Gastro-Oesophageal Junction Adenocarcinoma”. 2023. Molecular Medicine Communications 3 (02): 89-92. https://doi.org/10.55627/mmc.003.02.0461.